ArsenalBio Launches With $85M for “Programmable” T Cell Therapies

ArsenalBio Launches With $85M for “Programmable” T Cell Therapies

Source: 
Xconomy
snippet: 

Cell therapies are made by tinkering with a patient’s immune cells so that they can better recognize and destroy cancer cells. These drugs give patients another treatment option for certain cancers that haven’t responded to anything else. ArsenalBio CEO Ken Drazan aims to take cell therapy even further.